MAPK3 and neoplasm: We discovered that p-ERK1/2 levels were altered during CD13 inhibition, thus facilitating tumor cell sensitization to TRAIL-induced killing, in agreement with reports that CD13 inhibitor decreases the phosphorylation of MAPK5,8.